2024
Disparities in Receipt of Medications for Opioid Use Disorder Before and During the COVID-19 Pandemic in the US Veterans Health Administration.
Sung M, León C, Reisman J, Gordon K, Kerns R, Li W, Liu W, Mitra A, Yu H, Becker W. Disparities in Receipt of Medications for Opioid Use Disorder Before and During the COVID-19 Pandemic in the US Veterans Health Administration. Substance Use & Addiction Journal 2024, 29767342241293334. PMID: 39569566, DOI: 10.1177/29767342241293334.Peer-Reviewed Original ResearchMOUD receiptElixhauser Comorbidity IndexOpioid use disorderSocial determinants of healthVeterans Health Administration electronic health record dataElectronic health record dataUS Veterans Health AdministrationDeterminants of healthVeterans Health AdministrationHealth record dataProportion of veteransReceipt of medicationsSubstance useComorbidity indexTargeted outreach effortsUse disorderCOVID-19 pandemicProportion of patientsSocial determinantsReceipt of MOUDHealth AdministrationRecord dataEffect sizeMOUD engagementCalculated proportions
2023
Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout
Lea A, Leyden W, Sofrygin O, Marafino B, Skarbinski J, Napravnik S, Agil D, Augenbraun M, Benning L, Horberg M, Jefferson C, Marconi V, Park L, Gordon K, Bastarache L, Gangireddy S, Althoff K, Coburn S, Gebo K, Lang R, Williams C, Silverberg M. Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout. Clinical Infectious Diseases 2023, 76: 1727-1734. PMID: 36861341, PMCID: PMC10209434, DOI: 10.1093/cid/ciad084.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAdjusted risk ratioCOVID-19 hospitalizationMechanical ventilationTenofovir useHIV statusAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSevere coronavirus disease 2019 (COVID-19) outcomesSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) outcomesHuman immunodeficiency virus statusCohort of PWHCD4 cell countCharlson Comorbidity IndexCoronavirus 2 infectionHIV RNA levelsUnited States cohortBody mass indexCOVID-19 severityCOVID-19 vaccine availabilityReal-world analysisTenofovir exposureComorbidity indexMass index